Patent Assignment
Reel/Frame 059262/0780
Intellectual Property Security Agreement
Recorded: 2022-02-28
Pages: 46
Assignor
INHIBRX, INC.
Executed: 2022-02-18
Assignee
OXFORD FINANCE LLC
115 SOUTH UNION STREET, SUITE 300, ALEXANDRIA, VIRGINIA, 22314
Covered Properties
(51)
Serpin Fusion Polypeptides and Methods of Use Thereof
Serpin Fusion Polypeptides and Methods of Use Thereof
Application:
17/315,511 →
Publication:
US 2022/0324944
Serpin Fusion Polypeptides and Methods of Use Thereof
Pd-1 Single Domain Antibodies and Therapeutic Compositions Thereof
Non-Immunogenic Single Domain Antibodies
Application:
16/685,087 →
Publication:
US 2020/0140525
Multivalent and Multispecific DR5-Binding Fusion Proteins and Methods of Modulating Immune Cells
Multivalent and Multispecific OX40-Binding Fusion Proteins
PDL1-Binding Proteins
Multispecific Polypeptide Constructs Having Constrained CD3 Binding and Methods of Using the Same
Multispecific Polypeptide Constructs Having Constrained CD3 Binding and Related Methods and Uses
Application:
16/380,963 →
Publication:
US 2019/0330366
B7H3 Single Domain Antibodies and Therapeutic Compositions Thereof
Application:
17/283,902 →
Publication:
US 2023/0124851
5T4 Single Domain Antibodies and Therapeutic Compositions Thereof
DLL3 Single Domain Antibodies and Therapeutic Compositions Thereof
Multispecific Polypeptide Constructs Containing a Constrained CD3 Binding Domain and a Receptor Binding Region and Methods of Using the Same
Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
Application:
17/418,458 →
Publication:
US 2022/0089667
OX40-Binding Polypeptides and Uses Thereof
CD123-Binding Polypeptides and Uses Thereof
CD33-Binding Polypeptides and Uses Thereof
CLEC12a Binding Polypeptides and Uses Thereof
CD123 Targeted Immunotherapies
Application:
17/608,739 →
Publication:
US 2022/0315638
CD33 Targeted Immunotherapies
Cll-1 Targeted Immunotherapies
CD8-Binding Polypeptides and Uses Thereof
Application:
63/223,786 →
CD8-Binding Polypeptides and Uses Thereof
Application:
63/288,111 →
CD8-Targeted Modified Il-2 Polypeptides and Uses Thereof
Application:
63/223,798 →
CD8-Targeted Modified Il-2 Polypeptides and Uses Thereof
Application:
63/288,113 →
CD33 Targeted Immunotherapies
Application:
63/111,280 →
Formulations of DR5 Binding Polypeptides
Application:
63/151,131 →
NKP46-Binding Polypeptides and Uses Thereof
Application:
63/238,429 →
NKP46-Targeted Modified IL-2 Polypeptides and Uses Thereof
Application:
63/238,431 →
Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
Application:
17/170,854 →
Publication:
US 2021/0317205
Wap Domain Fusion Polypeptides and Methods of Use Thereof
Wap Domain Fusion Polypeptides and Methods of Use Thereof
Serpin Fusion Polypeptides and Methods of Use Thereof
Serpin Fusion Polypeptides And Methods Of Purification Thereof
Serpin Fusion Polypeptides and Methods of Use Thereof
Serpin Fusion Polypeptides and Methods of Use Thereof
Serpin Fusion Polypeptides and Methods of Use Thereof
Serpin Fusion Polypeptides and Methods of Use Thereof
Pd-1 Single Domain Antibodies and Therapeutic Compositions Thereof
Non-Immunogenic Single Domain Antibodies
Type Iii Secretion System Targeting Molecules
Type III Secretion System Targeting Molecules
Multivalent and Multispecific DR5-Binding Fusion Proteins
Multivalent and Multispecific DR5-Binding Fusion Proteins and Methods of Treating Neoplasms
Multispecific Gitr-Binding Fusion Proteins and Methods of Use Thereof
Multivalent and Multispecific Glucocorticoid-Induced Tnfr-Related Protein (Gitr)-Binding Single-Domain Antibody Fusion Proteins and Encoding Nucleic Acids
Multivalent and Multispecific OX40-Binding Fusion Proteins
Multivalent and Multispecific 41BB-Binding Fusion Proteins
CD47 Antibodies and Methods of Use Thereof
CD47 Antibodies and Methods of Use Thereof
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Merger and Change of Name
May 23, 2018
From: INHIBRX, LP; TENIUM THERAPEUTICS, INC.
To: INHIBRX, INC.
Reel/Frame 046216/0820 →
Corrective Assignment to Correct the Receiving Party Address Change Previously Recorded at Reel: 046216 Frame: 0820. Assignor(S) Hereby Confirms the Assignment.
Jul 2, 2018
From: INHIBRX, LP
To: INHIBRX, INC.
Reel/Frame 046635/0320 →
Assignment of Assignor's Interest
Sep 7, 2018
From: ECKELMAN, BRENDAN P.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; DEVERAUX, QUINN
To: INHIBRX, INC.
Reel/Frame 046813/0110 →
Assignment of Assignor's Interest
Jul 10, 2019
From: ECKELMAN, BRENDAN P.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; TIMMER, JOHN C.
To: INHIBRX, INC.
Reel/Frame 049714/0484 →
Assignment of Assignor's Interest
Nov 1, 2019
From: ECKELMAN, BRENDAN P.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; DEVERAUX, QUINN
To: INHIBRX, INC.
Reel/Frame 050895/0085 →
Change of Name
Oct 14, 2020
From: INHIBRX, LLC
To: INHIBRX, LP
Reel/Frame 054074/0330 →
Assignment of Assignor's Interest
Oct 14, 2020
From: ECKELMAN, BRENDAN; TIMMER, JOHN; NGUY, PETER L.; GUENTHER, GRANT B.
To: INHIBRX LLC
Reel/Frame 054046/0863 →
Assignment of Assignor's Interest
Oct 14, 2020
From: INHIBRX, LP
To: INHIBRX, INC.
Reel/Frame 054046/0981 →
Assignment of Assignor's Interest
Aug 5, 2021
From: TIMMER, JOHN C.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; PANDIT, RAJAY A.
To: INHIBRX, INC.
Reel/Frame 057097/0600 →
Assignment of Assignor's Interest
Aug 19, 2021
From: ECKELMAN, BRENDAN P.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; JONES, KYLE S.
To: INHIBRX, INC.
Reel/Frame 057234/0883 →
Assignment of Assignor's Interest
Aug 19, 2021
From: ECKELMAN, BRENDAN P.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; PANDIT, RAJAY A.
To: INHIBRX, INC.
Reel/Frame 057234/0983 →
Assignment of Assignor's Interest
Nov 16, 2021
From: PANDIT, RAJAY A.; TIMMER, JOHN C.; SANABRIA, ANGELICA N.; SULZMAIER, FLORIAN
To: INHIBRX, INC.
Reel/Frame 058121/0619 →
Assignment of Assignor's Interest
Feb 22, 2022
From: INHIBRX, LP
To: INHIBRX, INC.
Reel/Frame 059065/0321 →
Assignment of Assignor's Interest
Feb 22, 2022
From: ECKELMAN, BRENDAN; TIMMER, JOHN; NGUY, PETER L.; GUENTHER, GRANT B.
To: INHIBRX LLC
Reel/Frame 059065/0307 →
Change of Name
Feb 22, 2022
From: INHIBRX LLC
To: INHIBRX, LP
Reel/Frame 059217/0264 →
Merger and Change of Name
Mar 25, 2022
From: INHIBRX LP; TENIUM THERAPEUTICS, INC.
To: INHIBRX, INC.
Reel/Frame 059501/0951 →
Assignment of Assignor's Interest
Mar 25, 2022
From: ECKELMAN, BRENDAN P.; TIMMER, JOHN C.; DEVERAUX, QUINN
To: INHIBRX LP
Reel/Frame 059399/0899 →
Assignment of Assignor's Interest
Mar 25, 2022
From: INHIBRX, LP
To: INHIBRX, INC.
Reel/Frame 059399/0969 →
Assignment of Assignor's Interest
Mar 25, 2022
From: ECKELMAN, BRENDAN P.; TIMMER, JOHN C.; DEVERAUX, QUINN
To: INHIBRX LP
Reel/Frame 059401/0943 →
Assignment of Assignor's Interest
Mar 25, 2022
From: INHIBRX BIOPHARMA, LLC
To: INHIBRX LP
Reel/Frame 059401/0954 →
Assignment of Assignor's Interest
Mar 19, 2024
From: MACEDO, CHELSIE; JONES, KYLE; CRAGO, WILLIAM; HOLLANDS, ANDREW
To: INHIBRX, INC.
Reel/Frame 066819/0457 →
Assignment of Assignor's Interest
May 22, 2024
From: JONES, KYLE; CRAGO, WILLIAM; SANABRIA, ANGELICA; HOLLANDS, ANDREW
To: INHIBRX, INC.
Reel/Frame 067493/0933 →
Release of Security Interest
Jun 3, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: INHIBRX, INC.
Reel/Frame 067606/0247 →
Assignment of Assignor's Interest
Jun 6, 2024
From: TIMMER, JOHN C.; CRAGO, WILLIAM; JONES, KYLE; WILLIS, KATELYN
To: INHIBRX, INC.
Reel/Frame 067643/0315 →
Assignment of Assignor's Interest
Jun 10, 2024
From: INHIBRX, INC.
To: INHIBRX BIOSCIENCES, INC.
Reel/Frame 067680/0770 →